Listen to article
Pharmaceutical giants, AstraZeneca alongside the University of Oxford have launched a study to assess the safety and immune response of the COVID-19 vaccine they both developed in children.
According to a statement by the university, the new mid-stage trial will determine whether the vaccine is effective for people between the ages of 6 and 17 and likely to determine the next line of action.
No fewer than 300 volunteers will be enrolled for this exercise and first inoculations are expected this month, Oxford said.
The two-dose Oxford/AstraZeneca vaccine has been hailed as a ‘vaccine for the world’ because it is cheaper and easier to distribute than some rivals.
AstraZeneca has a target to produce 3 billion doses this year and aims to produce over 200 million doses per month by April.
AFRICA TODAY NEWS, NEW YORK